Browse studies
Find your next paid study
28 recruiting studies matching your filters
Phase 1
Phase I Trial of a Chimeric (Trastuzumab-like and Pertuzumab-like) HER2 B Cell Peptide Vaccine Emulsified in ISA 720 Adjuvant for Locally Advanced HER2 Positive Breast Cancer
The goal of this study is to test an investigational vaccine to activate the immune system to fight breast cancer.
Breast CancerHER2-positive Breast Cancer
Estimated
~$10 – $7,500
Pravin T.P KaumayaNCT06949410
Phase 2
An Open Label, Phase II Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Cancers Hoosier Cancer Research Network BRE17-141
Patient will be treated with neratinib, an aromatase inhibitor and trastuzumab for 24 weeks prior to surgery, following an initial 3 weeks of neratinib alone, …
Breast CancerHER2-positive Breast CancerER Positive Breast Cancer+1 more
Estimated
~$10 – $7,500
Ruth O'ReganNCT04886531
Observational
Prolonged Overnight Fasting and/or Exercise on Fatigue and Other Patient Reported Outcomes in Women With Hormone Receptor Positive Advanced Breast Cancer (FastER)
The purpose of this study is to test if four different programs (prolonged overnighting fasting alone, exercise alone, a combination of prolonged overnight fas…
HER2-positive Breast CancerAdvanced Breast Cancer
Estimated
~$10 – $6,250
University of MiamiNCT06123988
Phase 3
A Phase 3, Randomized, Open-label, Multicenter, Controlled Study to Evaluate the Efficacy and Safety of Zanidatamab in Combination With Physician's Choice Chemotherapy Compared to Trastuzumab in Combination With Physician's Choice Chemotherapy for the Treatment of Participants With Metastatic HER2-positive Breast Cancer Who Have Progressed on, or Are Intolerant to, Previous Trastuzumab Deruxtecan Treatment
The efficacy and safety of zanidatamab in combination with physician's choice of chemotherapy compared with trastuzumab in combination with physician's choice …
Metastatic HER2-positive Breast Cancer
Estimated
~$10 – $8,750
Jazz PharmaceuticalsNCT06435429